Latest News

Affluent Medical Releases Impressive Results from Scope 1 Clinical Trial Validating Efficacy of KARDIOZIS Technology




PARIS–(BUSINESS WIRE)–Affluent Medical (Paris:ALAM), a French medtech company specialized in innovative, minimally invasive implants designed to restore key physiological functions for patients suffering from heart and vascular diseases, as well as urinary incontinence, today announces positive results from its SCOPE 1 clinical trial validating the efficacy of KARDIOZIS technology. Results have been presented Saturday February 9th, 2019 at Controversies And Updates in Vascular Surgery congres

Source link

Related posts

CDRD Appoints Didier Leconte to Its Board of Directors

Newsemia

New generation of therapeutics based on understanding of aging biology show promise for Alzheimer's disease

Newsemia

Medical News Today: Mild cognitive impairment: Reducing blood pressure can lower risk

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World